Bicycle Therapeutics Ltd
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $676.90 million
- Book Value:
- Revenue TTM:
- $14.46 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Bicycle Therapeutics Ltd had its IPO on 2019-05-23 under the ticker symbol BCYC.
The company operates in the Healthcare sector and Biotechnology industry. Bicycle Therapeutics Ltd has a staff strength of 236 employees.
Shares of Bicycle Therapeutics Ltd opened at $21.87 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $21.02 - $22.12, and closed at $21.27.
This is a -2.3% slip from the previous day's closing price.
A total volume of 130,770 shares were traded at the close of the day’s session.
In the last one week, shares of Bicycle Therapeutics Ltd have increased by +4.52%.
Bicycle Therapeutics Ltd's Key Ratios
Bicycle Therapeutics Ltd has a market cap of $676.90 million, indicating a price to book ratio of 3.1395 and a price to sales ratio of 61.6912.
In the last 12-months Bicycle Therapeutics Ltd’s revenue was $14.46 million with a gross profit of $-67146000 and an EBITDA of $-112964000. The EBITDA ratio measures Bicycle Therapeutics Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Bicycle Therapeutics Ltd’s operating margin was -806.56% while its return on assets stood at -16.38% with a return of equity of -36.54%.
In Q4, Bicycle Therapeutics Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 15.5%.
Bicycle Therapeutics Ltd’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-4.22 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bicycle Therapeutics Ltd’s profitability.
Bicycle Therapeutics Ltd stock is trading at a EV to sales ratio of 39.296 and a EV to EBITDA ratio of -6.1231. Its price to sales ratio in the trailing 12-months stood at 61.6912.
Bicycle Therapeutics Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $410.61 million
- Total Liabilities
- $53.34 million
- Operating Cash Flow
- Capital Expenditure
- $1.45 million
- Dividend Payout Ratio
Bicycle Therapeutics Ltd ended 2023 with $410.61 million in total assets and $0 in total liabilities. Its intangible assets were valued at $410.61 million while shareholder equity stood at $270.78 million.
Bicycle Therapeutics Ltd ended 2023 with $0 in deferred long-term liabilities, $53.34 million in other current liabilities, 387000.00 in common stock, $-331096000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $339.15 million and cash and short-term investments were $339.15 million. The company’s total short-term debt was $3,125,000 while long-term debt stood at $30.32 million.
Bicycle Therapeutics Ltd’s total current assets stands at $369.38 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $21.21 million compared to accounts payable of $6.47 million and inventory worth $0.
In 2023, Bicycle Therapeutics Ltd's operating cash flow was $0 while its capital expenditure stood at $1.45 million.
Comparatively, Bicycle Therapeutics Ltd paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Bicycle Therapeutics Ltd stock is currently trading at $21.27 per share. It touched a 52-week high of $50.47 and a 52-week low of $50.47. Analysts tracking the stock have a 12-month average target price of $52.21.
Its 50-day moving average was $24.12 and 200-day moving average was $24.7 The short ratio stood at 8.52 indicating a short percent outstanding of 0%.
Around 986.8% of the company’s stock are held by insiders while 8933.7% are held by institutions.
Frequently Asked Questions About Bicycle Therapeutics Ltd
Similar Industry Stocks (Biotechnology)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528, a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA; and BT7401, a multivalent CD137 agonist. In addition, it collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, dementia, central nervous system, neuromuscular, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca AB, Sanofi, Oxurion NV, and the Dementia Discovery Fund, as well as with Ionis Pharmaceuticals, Inc.; and a discovery collaboration and license agreement with Genentech Inc. for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.